Low Molecular Weight Thyrotropin Receptor Inverse Agonist Is Active upon Both Intraperitoneal and Oral Administration
K. V. Derkach,A. A. Bakhtyukov,V. N. Sorokoumov,I. A. Lebedev,E. A. Didenko,A. O. Shpakov
DOI: https://doi.org/10.1134/s0022093024010216
2024-01-01
Journal of Evolutionary Biochemistry and Physiology
Abstract:Autoimmune hyperthyroidism (Graves’ disease), which is causedby stimulating autoantibodies to the thyroid-stimulating hormonereceptor (TSHR), and thyroid tumors, caused by a constitutivelyincreased activity of this receptor, are widespread and have a poorprognosis. The drugs used to treat them are low effective and havemany side effects. One of the therapeutic approaches to these thyroiddiseases may be the use of TSH receptor allosteric regulators withan activity of inverse agonists. This work was aimed to study theeffects of the compound TP48, previously synthesized in our laboratory,and a newly synthesized compound TPY5, with both of them referringto thieno[2,3-d]-pyrimidines, on basal and thyrotropin-releasinghormone (TRH)-stimulated levels of thyroid hormones (THs) in therat blood and on the expression of genes responsible for TH synthesisin the rat thyroid gland. TP48 and TPY5 effectiveness was studiedupon both intraperitoneal (20 mg/kg) and peroral (40 mg/kg) administration. UsingELISA, blood levels of free (fT4) and total (tT4) thyroxine, aswell as free (fT3) and total (tT3) triiodothyronine, were assessed,including during stimulation with intranasal TRH (300 µg/kg). Gene expressionfor thyroid peroxidase (Tpo),thyroglobulin (Tg), Na+/I– symporter(Nis), type 2 deiodinase (Dio2), and TSH receptor (Tshr) in the thyroid gland was assessedby PCR. TPY5, administered via both routes, reduced both basal andTRH-stimulated plasma TH levels, while TP48 suppressed TH productiononly after intraperitoneal administration. Peroral TPY5 significantlyreduced basal Tpo expression,as well as TRH-stimulated Tg and Dio2 expression. IntraperitonealTP48 reduced only TRH-stimulated Tg and Dio2 expression. Quite surprisingly,peroral TPY5 and intraperitoneal TP48 reduced basal Tshr expression but did not preventits inhibition by TRH. Thus, the novel compound TPY5 exhibits theactivity of a TSH receptor inverse agonist and is effective whenadministered perorally, which is more in demand in medicine; itcan be considered as a prototype of drugs to treat autoimmune hyperthyroidismand thyroid tumors.
biochemistry & molecular biology,evolutionary biology,physiology